Caveolae and Bin1 form ring-shaped platforms for T-tubule initiation

  1. Eline Lemerle
  2. Jeanne Lainé
  3. Marion Benoist
  4. Gilles Moulay
  5. Anne Bigot
  6. Clémence Labasse
  7. Angéline Madelaine
  8. Alexis Canette
  9. Perrine Aubin
  10. Jean-Michel Vallat
  11. Norma B Romero
  12. Marc Bitoun
  13. Vincent Mouly
  14. Isabelle Marty
  15. Bruno Cadot
  16. Laura Picas
  17. Stéphane Vassilopoulos  Is a corresponding author
  1. Sorbonne Université, INSERM, France
  2. Pitié-Salpêtrière Hospital, France
  3. Sorbonne Université, France
  4. University Grenoble Alpes, INSERM, France
  5. University Hospital, France
  6. CNRS UMR 9004, Université de Montpellier, France

Abstract

Excitation-contraction coupling requires a highly specialized membrane structure, the triad, composed of a plasma membrane invagination, the T-tubule, surrounded by two sarcoplasmic reticulum terminal cisternae. Although the precise mechanisms governing T-tubule biogenesis and triad formation remain largely unknown, studies have shown that caveolae participate in T-tubule formation and mutations of several of their constituents induce muscle weakness and myopathies. Here, we demonstrate that, at the plasma membrane, Bin1 and caveolae composed of caveolin-3 assemble into ring-like structures from which emerge tubes enriched in the dihydropyridine receptor. Bin1 expression lead to the formation of both rings and tubes and we show that Bin1 forms scaffolds on which caveolae accumulate to form the initial T-tubule. Cav3 deficiency caused by either gene silencing or pathogenic mutations results in defective ring formation and perturbed Bin1-mediated tubulation that may explain defective T-tubule organization in mature muscles. Our results uncover new pathophysiological mechanisms that may prove relevant to myopathies caused by Cav3 or Bin1 dysfunction.

Data availability

All datasets supporting the findings of this study are available in Dryad

The following data sets were generated

Article and author information

Author details

  1. Eline Lemerle

    Institut de Myologie, Sorbonne Université, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Jeanne Lainé

    Institut de Myologie, Sorbonne Université, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Marion Benoist

    Institut de Myologie, Sorbonne Université, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Gilles Moulay

    Institut de Myologie, Sorbonne Université, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Anne Bigot

    Institut de Myologie, Sorbonne Université, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Clémence Labasse

    Neuromuscular Morphology Unit, Pitié-Salpêtrière Hospital, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Angéline Madelaine

    Neuromuscular Morphology Unit, Pitié-Salpêtrière Hospital, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  8. Alexis Canette

    Institut de Biologie Paris-Seine, Sorbonne Université, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2750-6568
  9. Perrine Aubin

    Grenoble Institut des Neurosciences, University Grenoble Alpes, INSERM, Grenoble, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Jean-Michel Vallat

    Department of Neurology, University Hospital, Limoges, France
    Competing interests
    The authors declare that no competing interests exist.
  11. Norma B Romero

    Neuromuscular Morphology Unit, Pitié-Salpêtrière Hospital, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  12. Marc Bitoun

    Institut de Myologie, Sorbonne Université, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  13. Vincent Mouly

    Institut de Myologie, Sorbonne Université, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  14. Isabelle Marty

    Grenoble Institut des Neurosciences, University Grenoble Alpes, INSERM, Grenoble, France
    Competing interests
    The authors declare that no competing interests exist.
  15. Bruno Cadot

    Institut de Myologie, Sorbonne Université, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  16. Laura Picas

    Institut de Recherche en Infectiologie de Montpellier (IRIM), CNRS UMR 9004, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5619-5228
  17. Stéphane Vassilopoulos

    Institut de Myologie, Sorbonne Université, INSERM, Paris, France
    For correspondence
    s.vassilopoulos@institut-myologie.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0172-330X

Funding

Agence Nationale de la Recherche (ANR-21-CE13-0018-01)

  • Stéphane Vassilopoulos

Agence Nationale de la Recherche (ANR-18-CE17-0006-02)

  • Marc Bitoun

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Animal studies conform to the French laws and regulations concerning the use of animals for research and were approved by an external ethics committee (approval no. 00351.02 delivered by the French Ministry of Higher Education and Scientific Research).

Human subjects: For human studies, all individuals provided informed consent for muscle biopsies according to a protocol approved by the ethics committee of the Centre de Référence de Pathologie Neuromusculaire Paris-Est, Institut de Myologie, Assistance Publique-Hôpitaux de Paris, GH Pitié-Salpêtrière, Paris, France.

Copyright

© 2023, Lemerle et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 19
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Eline Lemerle
  2. Jeanne Lainé
  3. Marion Benoist
  4. Gilles Moulay
  5. Anne Bigot
  6. Clémence Labasse
  7. Angéline Madelaine
  8. Alexis Canette
  9. Perrine Aubin
  10. Jean-Michel Vallat
  11. Norma B Romero
  12. Marc Bitoun
  13. Vincent Mouly
  14. Isabelle Marty
  15. Bruno Cadot
  16. Laura Picas
  17. Stéphane Vassilopoulos
(2023)
Caveolae and Bin1 form ring-shaped platforms for T-tubule initiation
eLife 12:e84139.
https://doi.org/10.7554/eLife.84139

Share this article

https://doi.org/10.7554/eLife.84139

Further reading

    1. Cell Biology
    Yan Song, Linda J Fothergill ... Gene W Yeo
    Research Article

    Dynamic interactions between gut mucosal cells and the external environment are essential to maintain gut homeostasis. Enterochromaffin (EC) cells transduce both chemical and mechanical signals and produce 5-hydroxytryptamine to mediate disparate physiological responses. However, the molecular and cellular basis for functional diversity of ECs remains to be adequately defined. Here, we integrated single-cell transcriptomics with spatial image analysis to identify 14 EC clusters that are topographically organized along the gut. Subtypes predicted to be sensitive to the chemical environment and mechanical forces were identified that express distinct transcription factors and hormones. A Piezo2+ population in the distal colon was endowed with a distinctive neuronal signature. Using a combination of genetic, chemogenetic, and pharmacological approaches, we demonstrated Piezo2+ ECs are required for normal colon motility. Our study constructs a molecular map for ECs and offers a framework for deconvoluting EC cells with pleiotropic functions.

    1. Cell Biology
    Kaili Du, Hongyu Chen ... Dan Li
    Research Article

    Niemann–Pick disease type C (NPC) is a devastating lysosomal storage disease characterized by abnormal cholesterol accumulation in lysosomes. Currently, there is no treatment for NPC. Transcription factor EB (TFEB), a member of the microphthalmia transcription factors (MiTF), has emerged as a master regulator of lysosomal function and promoted the clearance of substrates stored in cells. However, it is not known whether TFEB plays a role in cholesterol clearance in NPC disease. Here, we show that transgenic overexpression of TFEB, but not TFE3 (another member of MiTF family) facilitates cholesterol clearance in various NPC1 cell models. Pharmacological activation of TFEB by sulforaphane (SFN), a previously identified natural small-molecule TFEB agonist by us, can dramatically ameliorate cholesterol accumulation in human and mouse NPC1 cell models. In NPC1 cells, SFN induces TFEB nuclear translocation via a ROS-Ca2+-calcineurin-dependent but MTOR-independent pathway and upregulates the expression of TFEB-downstream genes, promoting lysosomal exocytosis and biogenesis. While genetic inhibition of TFEB abolishes the cholesterol clearance and exocytosis effect by SFN. In the NPC1 mouse model, SFN dephosphorylates/activates TFEB in the brain and exhibits potent efficacy of rescuing the loss of Purkinje cells and body weight. Hence, pharmacological upregulating lysosome machinery via targeting TFEB represents a promising approach to treat NPC and related lysosomal storage diseases, and provides the possibility of TFEB agonists, that is, SFN as potential NPC therapeutic candidates.